Aleksandra Rizo
About
Aleksandra Rizo is a scholar working on Hematology, Genetics and Molecular Biology.
According to data from OpenAlex, Aleksandra Rizo has authored 28 papers receiving a total of 655 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 16 papers in Genetics and 10 papers in Molecular Biology. Recurrent topics in Aleksandra Rizo's work include Acute Myeloid Leukemia Research (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Aleksandra Rizo is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Aleksandra Rizo collaborates with scholars based in United States, France and Germany. Aleksandra Rizo's co-authors include Edo Vellenga, Jan Jacob Schuringa, Gerald de Haan, Sandra Olthof, Bert Dontje, Lina Han, Hein Schepers, Djoke van Gosliga, Eugene Zhu and Shalini Chaturvedi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Aleksandra Rizo
28 papers receiving 649 citations
Peers
Aleksandra Rizo
Claudiu Cotta United States
María José Larráyoz Spain
Daniela Intini Italy
Oreste Villani Italy
Maher Albitar United States
Eva Maria Murga Penas Germany
Stéphanie Struski France
Sanjiv Modi United States
Jacques Vargaftig France
T Flores Spain
Citations per year, relative to Aleksandra Rizo Aleksandra Rizo (= 1×)
peers
Claudiu Cotta
Countries citing papers authored by Aleksandra Rizo
Since
Specialization
Citations
This map shows the geographic impact of Aleksandra Rizo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleksandra Rizo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleksandra Rizo more than expected).
Fields of papers citing papers by Aleksandra Rizo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Aleksandra Rizo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleksandra Rizo. The network helps show where Aleksandra Rizo may publish in the future.
Co-authorship network of co-authors of Aleksandra Rizo
This figure shows the co-authorship network connecting the top 25 collaborators of Aleksandra Rizo. A scholar is included among the top collaborators of Aleksandra Rizo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aleksandra Rizo. Aleksandra Rizo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2022). P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR. HemaSphere. 6. 938–939.
2.
Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2022). Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncology. 18(22). 2393–2402.
3.
Santini, Valeria, Pierre Fenaux, Koen Van Eygen, et al.. (2021). On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Blood. 138(Supplement 1). 2598–2598.
4.
Kuykendall, Andrew, Libo Sun, John Mascarenhas, et al.. (2021). Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data. Annals of Hematology. 101(1). 139–146.
5.
Platzbecker, Uwe, Rami S. Komrokji, Pierre Fenaux, et al.. (2021). IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.. Journal of Clinical Oncology. 39(15_suppl). TPS7056–TPS7056.
6.
Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2021). A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi). Blood. 138(Supplement 1). 1503–1503.
7.
Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2020). A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor. Blood. 136(Supplement 1). 43–44.
8.
Kiladjian, Jean‐Jacques, John Mascarenhas, Rami S. Komrokji, et al.. (2020). Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis. Blood. 136(Supplement 1). 45–46.
9.
Ma, Wenxue, Yudou He, Cayla Mason, et al.. (2020). Imetelstat Inhibits Telomerase and Prevents Propagation of ADAR1-Activated Myeloproliferative Neoplasm and Leukemia Stem Cells. Blood. 136(Supplement 1). 18–18.
10.
Platzbecker, Uwe, David P. Steensma, Koen Van Eygen, et al.. (2019). Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood. 134(Supplement_1). 4248–4248.
11.
Kuykendall, Andrew, Ying Wan, John Mascarenhas, et al.. (2019). PS1456 FAVORABLE OVERALL SURVIVAL OF IMETELSTAT‐TREATED RELAPSED/REFRACTORY MYELOFIBROSIS PATIENTS COMPARED WITH CLOSELY MATCHED REAL WORLD DATA. HemaSphere. 3(S1). 669–670.
12.
Luistro, Leopoldo, Diana Chin, Melissa Smith, et al.. (2017). Abstract 1101: Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax enhances apoptosis in vitro and increases survival in vivo in acute myeloid leukemia. Cancer Research. 77(13_Supplement). 1101–1101.
13.
Rizo, Aleksandra, et al.. (2016). Abstract 2731: Impact of hypomethylating agents on hTERT expression and synergistic effect in combination with imetelstat, a telomerase inhibitor, in AML cell lines. Cancer Research. 76(14_Supplement). 2731–2731.
14.
Offner, Fritz, Olga Samoilova, Evgenii A. Osmanov, et al.. (2015). Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 126(16). 1893–1901.
15.
Wang, Michael, André Goy, Peter Martin, et al.. (2014). Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy. Blood. 124(21). 4471–4471.
16.
Wang, Michael, Leo I. Gordon, Simon Rule, et al.. (2013). A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL).. Journal of Clinical Oncology. 31(15_suppl). TPS8613–TPS8613.
17.
Rizo, Aleksandra, Sarah J. Horton, Sandra Olthof, et al.. (2010). BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. Blood. 116(22). 4621–4630.
18.
Gosliga, Djoke van, et al.. (2007). Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Experimental Hematology. 35(10). 1538–1549.
19.
Rizo, Aleksandra, Edo Vellenga, Gerald de Haan, & Jan Jacob Schuringa. (2006). Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche?. Human Molecular Genetics. 15(suppl_2). R210–R219.
20.
González-Barón, Manuel, Carlos García Girón, Manuel Constenla, et al.. (1997). 67 Phase II activity of gemcitabine + cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer. 18. 20–20.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Claudiu Cotta Breakdown of academic impact, for papers by María José Larráyoz Breakdown of academic impact, for papers by Daniela Intini Breakdown of academic impact, for papers by Oreste Villani Breakdown of academic impact, for papers by Maher Albitar Breakdown of academic impact, for papers by Eva Maria Murga Penas Breakdown of academic impact, for papers by Stéphanie Struski Breakdown of academic impact, for papers by Sanjiv Modi Breakdown of academic impact, for papers by Jacques Vargaftig Breakdown of academic impact, for papers by T Flores